Compare MI & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MI | BIAF |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | 57 |
| Industry | Catalog/Specialty Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.6M |
| IPO Year | 2022 | N/A |
| Metric | MI | BIAF |
|---|---|---|
| Price | $0.31 | $3.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 19.0M |
| Earning Date | 05-07-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.16 |
| 52 Week High | $6.70 | $13.50 |
| Indicator | MI | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 17.68 | 62.76 |
| Support Level | N/A | $0.76 |
| Resistance Level | $4.28 | $5.38 |
| Average True Range (ATR) | 0.07 | 0.92 |
| MACD | 0.04 | 0.13 |
| Stochastic Oscillator | 11.91 | 65.86 |
NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.